Aarhus University Seal / Aarhus Universitets segl

Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Annette Langager Høgh
  • Steen Vammen, Department of Vascular Surgery, Skejby Sygehus, University hospital of Aarhus, Denmark
  • Lars Jørgen Østergaard
  • Jette B Joensen, Department of Vascular Surgery, Rigshospitalet, Denmark
  • Esklid W Henneberg, Vascular Research Unit, Department of Vascular Surgery, Viborg Hospital, Denmark
  • Jes S. Lindholt
Background: Antibodies against Chlamydia pneumoniae are associated with an increased rate of expansion of small abdominal aortic aneurysms (AAAs). Short-term follow-up trials have shown a transient reduction AAA growth rate, in macrolide treated compared with placebo. Therefore we analysed the influence of intermittent, long-term roxithromycin treatment on AAA expansion and referral for surgery. Methods: Eighty-four patients with small AAAs were randomized to either an annual 4 weeks' treatment with roxithromycin or placebo, and followed prospectively. Results: Intermittent, long-term Roxithromycin-treatment reduced mean annual growth rate by 36% compared with placebo after adjustment for potential confounders. Long-term roxithromycin-treated patients had a 29% lower risk of being referred for surgical evaluation, increasing to 57% after adjusting for potential confounders. Conclusion: Annual 4 week treatment with 300 mg roxithromycin daily may reduce the progression of small AAAs, and later need for surgical repair. However, more robust studies are needed for confirmation.
Original languageEnglish
JournalVascular and Endovascular Surgery
Pages (from-to)452-456
Number of pages4
Publication statusPublished - 2009

See relations at Aarhus University Citationformats

ID: 18057764